“Threshold of Cognitive Impairment after HIV Infection: Effect of Morphine”
Principal Investigator: David J. Volsky, Ph.D.
Agency: National Institute of Drug Abuse, NIH
Type: R01 DA 037611; Period: 04/01/2014-03/31/2019
The goal of this project is to study the role of morphine in HIV-mediated neuropathogenesis.
“CNS Reservoirs of HIV in a Mouse Model of HIV Infection and Cognitive Impairment: Eradication Strategies”
Principal Investigator: David J. Volsky, Ph.D.
Agency: National Institute of Mental Health, NIH
Type: R01 MH 104145-01; Period: 07/01/2014–04/30/2019
The major goal of this project is to study the nature of HIV reservoirs in the brain and evaluate strategies for their elimination in mice.
“Intranasal Insulin Therapy for HIV-Associated Neurocognitive Disorders”
Principal Investigators: McArthur & Haughey, MPI
Principal Investigators: David J. Volsky and Barbara Slusher, Dual PI in Project 2
Agency: National Institute of Mental Health, NIH
Type: P01 MH 105280-01A1; Period: 09/01/2015–05/31/2020
The major goal of this project is to study mitigation of HIV-induced cognitive disease by intranasal insulin treatment in an animal model and in patients.
“Toward Control of HIV Neuropathogenesis by Innate Immunity”
Principal Investigators: Mary Jane Potash & David J. Volsky
Agency: National Institute of Neurological Disorders and Stroke/NIH
Type: 1 R01 NS 094146-01A1; Period: 04/01/2016–03/31/2021
The goal of this project is to define the basis of protective innate immune responses of macrophages to HIV in mice to prevent HIV infection in the brain or its associated brain disease.
“Effect of Buprenorphine on Monocytes in the Context of NeuroAIDS and Opioid Abuse”
Principal Investigators: Joan Berman & David J. Volsky
Agency: National Institute on Drug Abuse/NIH
Type: 1 R01 DA 041931-01A1; Period: 04/15/2017–06/30/2022
The overall goal of this project is to investigate the potential dual mechanism of action of buprenorphine as an opiate antagonist and inhibitor of monocyte migration to the brain, thus establishing buprenorphine as a dual-action agent for treatment of both opiate abuse and cognitive disease in HIV-infected individuals.